Pharmacological interventions on critical limb ischemia in diabetic patients

Journal of Cardiovascular Surgery

Volumn 53, Issue 1, 2012, Pages 39-43

  Parekh, N ^a   Nanjundappa, A ^b   Dieter, R S ^c  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b Department of Cardiology ^*  (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Diabes mellitus; Ischemia; Lower extremities

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBROBLAST GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1; RAMIPRIL; SCATTER FACTOR; ADRENERGIC RECEPTOR STIMULATING AGENT; VASODILATOR AGENT;

CRITICAL LIMB ISCHEMIA; DIABETIC PATIENT; DRUG MECHANISM; EARLY DIAGNOSIS; ENDOVASCULAR SURGERY; GENE THERAPY; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; INFECTION COMPLICATION; LIMB ISCHEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; RISK FACTOR; STROKE; CRITICAL ILLNESS; DIABETIC ANGIOPATHY; ISCHEMIA; LEG; TREATMENT OUTCOME; VASCULARIZATION;

ADRENERGIC AGENTS; CRITICAL ILLNESS; DIABETIC ANGIOPATHIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISCHEMIA; LEG; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84857163539     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Dieter R, Dieter R, Dieter R. Peripheral Arterial Disease 2009;42:827-41.
2. Gottsater A. Managing risk factors for atherosclerosis in critical limb ishcemia. Eur J Vasc Endovasc Surg 2006;32:478-83-
3. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic InterSociety Concensus (TASC). J Vasc Surg 2000;31:S1-S296.
4. Adler AI, Stevens RJ, Neil A, Straton IM, Boulton AJ, Holman RR. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002;25:894-9. (Pubitemid 41094289)
5. Da Silva A, Widmer LK, Ziegler HW, Nissen C, Schweizer W. The Basle longitudinal study: report on the relation of initial glucose level to baseline ECG abnormalities, peripheral artery disease, and subsequent mortality. J Chronic Dis 1979;32:797-803. (Pubitemid 10168157)
6. Virkkunen J, Heikkinen M, Lepantalo M, Metsanoja R, Salenius JP. Diabetes as an independent risk factor for early post-operative complications in critical limb ischemia. J Vasc Surg 2004;40:761-7. (Pubitemid 39311645)
7. Willigendael EM, Teijink JA, Bartelink ML, Kuiken BW, Boiten J, Moll FL et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg 2004;40:1158-65. (Pubitemid 40037284)
8. Smith I, Franks PJ, Greenhalgh RM, Poulter NR, Powell JT. The influence of smoking cessation and hypertriglyceridemia on the progression of peripheral arterial disease and the onset of critical limb ischemia. Eur J Vasc Endovasc Surg 1996;11:402-8. (Pubitemid 26192843)
9. Ameli FM, Stein M, Provan JL, Prosser L. The effects of postoperative smoking on femoropopliteal bypass grafts. Ann Vasc Surg 1989;3:20-5.
10. Quick CR, Cotton LT. The measured effect of stopping smoking on intermittent claudication. Br J Surg 1982;69(Suppl.):S24-S6.
11. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction, and mortality. Acta Med Scand 1987;221:253-60. (Pubitemid 17069424)
12. Rooke T, Sullivan T, Jaff M. Medical Treatment of Peripheral Arterial Disease. Vascular Medicine and Endovascular Interventions 2007;14:163-8.
13. Hirsch AT, Treat-Jacobson D, Lando HA, Hatsukami DK. The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. Vasc Med 1997;2:243-51. (Pubitemid 27468159)
14. Cheng SW, Ting AC. Lipoprotein (a) level and mortality in patients with critical lower limb ischemia. Eur J Vasc Endovasc Surg 2001;22:124-9. (Pubitemid 32737454)
15. Buchwald H, Hunter DW, Tuna N, Williams SE, Boen JR, Hansen BJ et al. Myocardial infarction and percent arteriographic stenosis of culprit lesion: report from the Program on the Surgical Control of the Hyperlipidemia (POSCH). Atherosclerosis 1998;138:391-401. (Pubitemid 28313525)
16. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998;351:1755-62. (Pubitemid 28269185)
17. Barani J, Nilsson JA, Mattiasson I, Lindblad B, Gottsater A. Inflammatory mediators are associated with 1-year mortality in critical limb ischemia. J Vasce Surg 2005;42:75-80. (Pubitemid 40966079)
18. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am J Cardiol 1995;75:894-903.
19. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
20. Takahara M, Kaneto H, Iida O, Gorogawa S, Katakami N, Matsuoka TA et al. The Influence of Glycemic Control on the Prognosis of Japanese Patients Undergoing Percutaneous Transluminal Angioplasty for Critical Limb Ischemia. Diabetes Care 2010;33:2538-42.
21. Gaede P, Vedel P, Larsen N, Jensen G, Parving HH, Pederson O. Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes. NEJM 2003;348:383-93. (Pubitemid 36159355)
22. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000;342:145-53.
23. Henke PK, Blackburn S, Proctor MC, Stevens J, Mukherjee D, Rajagopalin S et al. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. J Vasc Surg 2004;39:357-65. (Pubitemid 38174318)
24. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
25. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
26. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
27. Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
28. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994;308:159-68.
29. Fowkes FGR, Price JF, Stewart MCW, Butcher I, et al. Aspirin for Prevention of Cardiovascular Events in a General Population Screened for a Low Ankle Brachial Index. JAMA 2010;303:841-8.
30. CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel versus aspirin in patients at risk for ischemic events (CAPRIE). Lancet 1996;348:1329-39.
31. Bhatt D, Fox K, Hacke W, Berger P, et al. Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. NEJM 2006;354:1706-17.
32. Ghosh R, Walsh SR, Tang TY, Noorani A, Hayes PD. Gene therapy as a novel therapeutic option in the treatment of peripheral vascular disease: systemic review and meta-analysis. Int J Clin Pract 2008;62:1383-90.
33. De Haro J, Acin F, Lopez-Quintana A, Florez A, Martinez-Aguilar E, Varela C. Meta-analysis of randomized, controlled clinical trials in angiogenesis: gene and cell therapy in peripheral arterial disease. Heart Vessels 2009;24:321-8.